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The role of cardiac magnetic resonance (CMR) in the 




Myocardial pathologies are significant causes of  morbidity and mortality in patients worldwide. Ischemic and non-ischemic 
cardiomyopathies have become a worldwide epidemic of  the 21st century with an increasing impact on health care systems. The 
2012 European Society of  Cardiology and 2013 American College of  Cardiology Foundation/American Heart Association guidelines 
provide current therapy guidance to reduce mortality and morbidity.
Methods
This was a systematic review involving cardiac magnetic resonance (CMR) studies for the diagnosis of  cardiomyopathy from January 
2013 to April 2017. Out of  62 reviewed studies, only 12 were included in our study.
Results
The average sensitivity and specificity of  CMR in the diagnosis of  cardiomyopathy was 86.75% (95% confidence interval [CI], 70.30% 
to 92.58%) and 81.75% (95% CI, 73.0% to 87.6%), respectively, and the positive predictive and negative predictive values were 80.17% 
and 86.75%, respectively.
Conclusion
Despite some limitations, our study shows that CMR has high sensitivity, specificity, and positive predictive value in diagnosing different 
types of  cardiomyopathy. CMR may be used to differentiate types of  cardiomyopathy, accurately quantify the chamber dimensions, 
volumes, and cardiac function, which make it useful for prognosis as well.
Keywords: Cardiac magnetic resonance, dilated cardiomyopathy, hypertrophic cardiomyopathy, ischemic cardiomyopathy, late 
gadolinium enhancement
Introduction
Myocardial pathologies are significant causes of  morbidity 
and mortality in patients worldwide. Ischemic and non-
ischemic cardiomyopathies have become a worldwide 
epidemic of  the 21st century with an increasing impact 
on health care systems. The 2012 European Society of  
Cardiology and 2013 American College of  Cardiology 
Foundation/American Heart Association guidelines 
provide current therapy guidance to reduce mortality and 
morbidity1,2,3,4. The revascularization of  coronary arteries 
in acute myocardial infarction has become the treatment 
of  choice, and revascularization procedures have evolved 
significantly. Coronary angiography is invasive and provides 
information only on the anatomical status of  obstructive 
coronary lesions. Several non-invasive methods have been 
developed to aid in the assessment of  the functional state 
of  the myocardium, namely contraction and perfusion, 
as well as microvascular and cellular integrity, including 
positron emission tomography and contrast, enhanced 
echocardiography5,6,7,8. More recently, the development of  
delayed contrast-enhanced magnetic resonance imaging 
(DE-MRI) has served a purpose as another imaging tool. 
In ischemic cardiomyopathy, the sub-endocardium is always 
enhanced on DE-MRI, while a patchy mid-myocardial 
enhancement is observed in dilated cardiomyopathy (DCM). 
Furthermore, patients with restrictive cardiomyopathy 
showed delayed myocardial improvement over the entire sub-
endocardial circumference9,10,11,12. Heart failure represents 
the final stage in the continuum of  cardiovascular diseases. 
Cardiac remodelling is a key component of  heart failure 
that progresses from adaptive to maladaptive as the disorder 
worsens. Increased myocardial wall stress during diastole 
contributes to the development and progression of  adverse 
cardiac remodeling13,14,15. Cardiac magnetic resonance 
is superior to other cardiac imaging modalities such as 
echocardiography, computed tomography angiography 
and coronary angiography in determining the type of  
cardiomyopathy, and cardiac function16,17.
Methods
Patient characteristics
The age of  participants in the included 12 cardiomyopathy 
studies ranged from 18 to 87 years, with dilated 
cardiomyopathy being a more seen pathology in the 
studies followed by ischemic cardiomyopathy. The patient 
characteristics are summarized in Table 1.
Identification of studies and journals
We identified published studies using CMR in the diagnosis 
of  different types of  cardiomyopathy in original and review 
articles by systematic searches of  PubMed, MedLine, 
Cochrane database and Embase, and by manual searches of  
listed references in the papers, we found. We limited our search 
to studies published from January 2013 to April 2017 because, 
during this period, we noted an increase in the application of  
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CMR in diagnosing different types of  cardiomyopathy. The 
keywords used were: “dilated cardiomyopathy”, “ischemic 
cardiomyopathy”, “hypertrophic cardiomyopathy”, 
“myocarditis”, “cardiac amyloidosis”, “cardiac sarcoidosis”, 
and “cardiac MR”, or “LGE CMR” (late gadolinium 
enhancement cardiovascular magnetic resonance), “Cine 
CMR”, and “sensitivity” or “specificity”. We identified 62 
studies through this search strategy. We further screened 
the reference list of  the retrieved studies for any additional 
publications. There were no restrictions on studies based on 
their sample size.
Eligibility criteria
We considered all eligible studies that evaluated the role of  
CMR in the diagnosis of  cardiomyopathy. We also included 
studies with sufficient information to allow the calculation 
of  sensitivity and specificity. We excluded meeting reports, 
abstracts, and reviews whose final stories were unavailable.
Data extraction
For each eligible study, we extracted the following 
information: author names, journal, year of  publication, 
number of  enrolled patients, the age of  study patients, study 
design, and CMR protocol.
Statistical analysis 
Statistical analysis was done using MedCalc for Windows 
version 64 bits; we calculated the sensitivity, specificity, 
positive predictive value, negative predictive value, positive 
likely-hood ratio, and negative likelihood ratio.
Results
Eligible studies
The search yielded 35 relevant studies. Of  these, due to 
limited data, 23 studies were excluded, and 12 studies were 
available for systematic review. Figure 1 summarizes the flow 
diagram of  how eligible studies were obtained. These studies 
were selected because they related to our analysis, they were 
recent, and they had likely extractable data as shown in figure 
1.
Figure 1: The flow diagram of study selection 
process for systematic review
Table 1: Characteristics of patients
Category
Sample size information
Total number of patients included 999
Number of studies reporting on sample size 12
Range of sample size reported 23-150
Age of participants
Number of studies reporting on age 10















Abbreviations: NICM= nonischemic cardiomyopathy, DCM= dilated 
cardiomyopathy





Goebel et al.18 
2016
150 T1 mapping 
CMR
Does not differentiate healthy and diffusely 
diseased myocardium
Makoto et al.19 
2016
44 LGE CMR LE in CS predominantly basal, mid septum 
and throughout the LV, while in DCM, LE was 
localized in the basal and mid septum
Mikami et al.20 
2016
118 LGE CMR Septal fibrosis
Okada et al.21 
2016
102 LGE CMR TIC had a significant lower RVEF, and a 
larger RVEDV and RVEDS
Kwong et al.22 
2015
81 Cine SSFP 
and LGE
CA mean proportion of atrial enhancement 
was significantly greater compared to SH and 
NIDCM
Maurizio et al.23 
2015
77 LGE CMR Hypertrophied septum indicating regional 
fibrosis in HCM
Schwab et al.24 
2015
43 CMR Wall motion abnormalities





Dungu et al.26 
2013
97 LGE CMR Distinguished ATTR from AL cardiac 
amyloidosis
Ferreira et al.27 
2013
50 T1 mapping 
CMR
T1 mapping is a criterion for detection of 
acute myocarditis with a higher sensitivity




Classification of distribution of trabeculation, 
43.9% global type, 56.2% apical type
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Abbreviations: CMR= cardiac magnetic resonance, LGE= late gadolinium 
enhancement, LE= late enhancement, CS= cardiac sarcoidosis, DCM= 
dilated cardiomyopathy, TIC= tachycardia induced cardiomyopathy, 
RVEDV= right ventricle end diastolic volume, RVEDS= right ventricle 
end systolic volume, CA= cardiac amyloidosis, SH= systemic hypertension, 
NIDCM= Nonischemic dilated cardiomyopathy, HCM= hypertrophic 
cardiomyopathy, AL= amyloid light chain, ATTR= transthyretin related 
Amyloidosis, SSFP= steady state free precision
Table 3: Showing individual studies with sensitivity, specificity and 
confidence intervals
Study Sensitivity 95% CI Specificity 95% CI F P R ( 1 -
TPR)
Goebel et al.18 2016 0.85 0.75-0.91 0.75 0.66-0.83 0.15
Makoto et al.19 2016 0.68 0.57-0.78 0.63 0.53-0.72 0.32
Mikami et al.20 2016 0.70 0.60-0.79 0.71 0.61-0.80 0.30
Okada et al.21 2016 0.88 0.79-0.95 0.75 0.66-0.82 0.12
Kwong et al.22 2015 0.93 0.85-0.97 0.80 0.71-0.87 0.07
Maurizio et al.23 2015 0.99 0.93-1.00 0.83 0.75-0.89 0.01
Schwab et al.24 2015 0.86 0.72-0.95 1.0 0.90-1.0 0.14
Nguyen et al.25 2015 0.84 0.75-0.95 0.80 0.72-0.88 0.16
Dungu et al.26 2013 0.96 0.89-0.99 0.88 0.80-0.93 0.04
Ferreira et al.27 2013 0.91 0.83-0.96 0.90 0.82-0.95 0.09
Choi et al.28 2016 0.85 0.76-0.92 0.76 0.64-0.83 0.15
Gulsin et al.29 2017 0.96 0.90-0.99 1.00 0.96-1.0 0.04
Abbreviations: CI= confidence interval, FPR= false positive rate, TPR= 
true positive rate
Table 4: Showing individual studies with positive predictive value 
and negative predictive value
Study PPV NPV
Goebel et al.18 2016 0.71 0.87
Makoto et al.19 2016 0.57 0.73
Mikami et al.20 2016 0.72 0.69
Okada et al.21 2016 0.69 0.91
Kwong et al.22 2015 0.76 0.94
Maurizio et al.23 2015 0.80 0.99
Schwab et al.24 2015 1.00 0.85
Nguyen et al.25 2015 0.81 0.85
Dungu et al.26 2013 0.87 0.96
Ferreira et al.27 2013 0.97 0.90
Choi et al.28 2016 0.72 0.88
Gulsin et al.29 2017 1.00 0.96
Abbreviations: PPV= positive predictive value, NPV= negative predictive value
Study description and patient characteristics
The 12 studies had a total of  999 patients. The sample size 
of  the studies ranged from 23 to 150. The age range of  the 
study subjects, 18 to 87 years, was reported in 10 reviews. 
Dilated cardiomyopathy was more prevalent in the studies, 
followed by ischemic cardiomyopathy and the least pervasive 
was cardiac sarcoidosis. The average sensitivity and specificity 
of  CMR in the diagnosis of  cardiomyopathy was 86.75% 
(95% confidence interval [CI], 70.30% to 92.58%) and 
81.75% (95% CI, 73.0% to 87.6%), respectively. The positive 
predictive and negative predictive values were 80.17% and 
86.75%. Tables 1, 2, 3, and 4 summarize the results.
Discussion
Cardiomyopathy has been diagnosed and assessed by 
echocardiogram or cardiac computed tomography for many 
years. With technological advancements and further research, 
several studies have addressed the role of  cardiac magnetic 
resonance (CMR) as a functional modality in the diagnosis 
and quantification of  cardiac function in different types of  
cardiomyopathy. CMR can measure and quantify chamber 
sizes and left ventricle (LV) systolic function accurately. 
Therefore, Cardiac Magnetic Resonance has potential as a 
tool to assess patient prognosis.
In our systematic review of  12 studies, we found moderately 
high sensitivity and specificity values for CMR, which 
implies that CMR is a standard valuable imaging modality 
for diagnosing different types of  cardiomyopathy. Goebel 
et al. could differentiate between dilated cardiomyopathy, 
hypertrophic cardiomyopathy (HCM), and healthy heart 
function through left ventricle quantification; patients 
with dilated cardiomyopathy had higher left ventricle end-
diastolic volume, end-systolic volume, and systolic volume 
and significantly lower ejection fractions compared to 
patients with healthy hearts18. Hypertrophic cardiomyopathy 
patients had substantially higher end-diastolic septum 
thickness compared to healthy subjects18. This reinforces 
the importance of  cardiac magnetic resonance in diagnosing 
cardiomyopathy. CMR can also be useful in differentiating 
ischemic and non-ischemic cardiomyopathy, which might 
facilitate optimal management of  patients.
According to this study, we appreciate the ability of  CMR 
to diagnose and differentiate types of  cardiomyopathies, 
through its high spatial resolution and tomographic image 
capabilities. Late gadolinium magnetic resonance was able to 
distinguish cardiac sarcoidosis and dilated cardiomyopathy19. 
Furthermore, Late Gadolinium Enhancement cardiac 
magnetic resonance was also used to diagnose non-ischemic 
Dilated cardiomyopathy by revealing septal fibrosis and 
other studies identified a mid-wall septal striae pattern 
of  Late gadolinium enhancement to be the most reliable 
predictor of  future events20. Moreover, CMR was also used 
to assess the diagnostic value of  early right ventricular 
dysfunction to predict tachycardia-induced cardiomyopathy, 
in which the studies revealed that CMR imaging assessing 
right ventricular function might be valuable compared with 
echocardiography21.
Ischemic cardiomyopathy can easily be missed in routine 
screening of  suspected coronary heart disease patients 
particularly in microvascular coronary artery disease whereby 
coronary angiogram may be the standard investigation 
expected to be done. But with the current new technology of  
Positron emission magnetic resonance imaging (PETMRI), 
it will be easy to know which areas are poorly perfused and 
confirmed by measuring coronary flow reserve30. Among 
other non-invasive imaging modalities, CMR is emerging as 
a highly sensitive and specific test for myocardial ischemia 
and infarction. Resting perfusion in CMR is used to evaluate 
microvascular obstruction, which is shown to predict adverse 
left ventricular remodelling31. Thus, as previous studies 
have indicated, the significance of  magnetic resonance in 
diagnosing different types of  cardiomyopathies especially in 
differentiating ischemic versus nonischemic cardiomyopathy, 
we concur with our results of  MRI having high sensitivity 
and specificity.
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Clinical implications
CMR is superior in evaluating cardiac function, LV 
dimensions, and capable of  differentiating types of  
cardiomyopathies with a specificity of  81.75% and 
sensitivity of  86.75%. In the clinical setting, the ability to 
diagnose the form of  cardiomyopathy helps in choosing 
the specific treatment. In a study of  Choi et al.,28 they used 
cardiac magnetic resonance imaging to establish refined 
diagnostic criteria for left ventricle non-compaction. As a 
quantitative approach, we have shown that a trabeculated 
left ventricle volume of  >35% of  the LV myocardial volume 
is diagnostic for left ventricle non-compaction with high 
specificity. Our study has also shown the diagnostic accuracy 
of  late gadolinium-enhanced cardiac magnetic resonance for 
establishing the etiology of  heart failure. Late gadolinium 
enhancement–cardiac magnetic resonance (LGE-CMR) was 
able to differentiate between ischemic cardiomyopathy and 
non-ischemic cardiomyopathy. Furthermore, the addition of  
adenosine stress perfusion-cardiac magnetic resonance (SP-
CMR) to cine and LGE-CMR provided minimal incremental 
diagnostic yield for determining the etiology of  heart failure 
in patients with severe left ventricle systolic dysfunction29. 
Limitations
The inclusion of  studies with small sample sizes may 
influence the statistical power of  the individual research and 
lead to imprecise and inconclusive results. Other limitations 
include bias through selection, publication, and verification 
of  the studies.
Conclusion
Despite some limitations, our study shows that cardiac 
magnetic resonance (CMR) has high sensitivity, specificity, 
and positive predictive value in diagnosing different types 
of  cardiomyopathy. CMR may be used to differentiate 
types of  cardiomyopathy, accurately quantify the chamber 
dimensions, volumes, and cardiac function which make it 
useful for prognosis as well.
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